randomized controlled trials demonstrating equivalent long-term outcomes across both treatment strategies, and significantly less societal cost associated with triple therapy 1 Switching to a bDMARD or tsDMARD of a different class is conditionally recommended over switching to a bDMARD or tsDMARD belonging to the same class for patients taking a bDMARD or tsDMARD who are not at target The recommendation is based on very low-certainty evidence supporting greater improvement in disease activity